Predictive tools for stabilization of therapeutic proteins

mAbs

Volumn 1, Issue 6, 2009, Pages 580-582

  Voynov, Vladimir ^a   Chennamsetty, Naresh ^a   Kayser, Veysel ^a   Helk, Bernhard ^b   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aggregation; Enhanced protein stability; Genetic engineering; Molecular simulations; Therapeutic antibodies

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; SHELF LIFE;

ALGORITHMS; AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; BAYES THEOREM; COMPUTATIONAL BIOLOGY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; SOFTWARE;

EID: 77952471578     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.6.9773     Document Type: Article

References (19)

1. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature 1957; 180:326-328
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7:21-39.
3. Carter PJ. Potent antibody therapeutics by design. Nature reviews 2006; 6:343-357
4. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93:1390-1402 (Pubitemid 38725014)
5. Cordoba-Rodriguez RV. Aggregates in MAbs and Recombinant Therapeutic Proteins: A Regulatory Perspective. BioPharm International 2008; 21:44-53.
6. Baynes BM, Trout BL. Rational design of solution additives for the prevention of protein aggregation. Biophys J 2004; 87:1631-1639
7. Baynes BM, Wang DI, Trout BL. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 2005; 44:4919-4925
8. Schneider CP, Trout BL. Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J Phys Chem B 2009; 113:2050-2058
9. Strickler SS, Gribenko AV, Keiffer TR, Tomlinson J, Reihle T, Loladze VV, Makhatadze GI. Protein stability and surface electrostatics: a charged relationship. Biochemistry 2006; 45:2761-2766 (Pubitemid 43334524)
10. Lawrence MS, Phillips KJ, Liu DR. Supercharging proteins can impart unusual resilience. J Am Chem Soc 2007; 129:10110-10112
11. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003; 424:805-808 (Pubitemid 37021713)
12. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 2005; 14:2723-2734 (Pubitemid 41395598)
13. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004; 22:1302-1306 (Pubitemid 39336784)
14. Klimov DK, Thirumalai D. Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets. Structure 2003; 11:295-307. (Pubitemid 36287693)
15. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 2009; 106:11937-11942
16. Anonymous. Computational biology: Unstuck by design. Nature 2009; 460:155.
17. Black SD, Mould DR. Development of Hydrophobicity Parameters to Analyze Proteins Which Bear Posttranslational or Cotranslational Modifications. Analytical Biochemistry 1991; 193:72-82.
18. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Predicting Aggregating Regions of Therapeutic Proteins. Submitted.
19. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-Prone Motifs in Human Immunoglobulin G. J Mol Biol 2009; 391:404-13.